Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2027 PD Study in DLB and PDD
NCT04764669Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of Irsenontrine in dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), sponsored by Eisai Co., Ltd.. Started Feb 2021; status: completed.
02
Drugs
Irsenontrine
03
Conditions
dementia with Lewy bodies (DLB)Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT04764669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04764669.